We would love to hear your thoughts about our site and services, please take our survey here.
Company now needs a major player to scale this breakthrough tech. The likes of Halma,Stryker,S&N could all quickly scale Steriwave now its gaining universal recognition and increased adoption. Consultants lead change and Steriwave is changing HAI post surgery. No brainer.
"Surgical site infections are devastating. If you look at a surgical site infection in a total joint replacement, it’s a months-long recovery process,” says Dr. Andrew Glennie, a QEII orthopaedic surgeon and clinical champion for the Steriwave “test-and-try" in Canada.
Steriwave is currently trialing in NHS.
From X.....
Ondine Biomedical
@OndineBio
·
Mar 18
"It is a no-brainer for us and the nurses are very excited to be involved.”
Read about how the team at the #QEII Health Sciences Centre is using Ondine’s Steriwave technology. Special thanks to the
@QEIIFoundation
for funding this year-long study.
I don't think that the true relevance of this contract has been evaluated by the investment community....yet.
NHS policy is used as a guide globally since it's decisions have major effects of its overall budget. This adoption of Steriwave after evaluation of a 6 month pilot was after a stringent cost/benefit analysis by one of its senior assessment authorities. The big point is that it's being used in orthopaedic pre-op which is a field change from the recent 77% reduction in HAI's in London oropharyngeal surgery.
This is a pivotal RNS and exactly what I suspected in my last post. This really does open the door for Steriwave adoption across the NHS. YHEC is one of the prime influences within the NHS and acts as a first mover in many cases of national rollout. Excellent news that their pilot and subsequent appraisal has led to adoption. The cost savings if universally adopted across the NHS would be 'substantial' according to Ondine.
As far as I can make out YHEC is undertaking an economic analysis based on results from primarily the Pontefract trial. I would expect conclusions from that are due any time. Since YHEC is an influencer for NHS policy it will look at savings that adoption of Steriwave could achieve. This could be quite a pivotal time for Ondine. Positive studies across the globe are accumulating.
The buying of big chunks continues. £175k is a lot of confidence. There is also the compelling case to bring this under the umbrella of eg Halma Stryker or S&N to grab the traction now. Interesting and huge potential. The benefits wrt Mupirocin are constantly being uprated.
Agree. It's like the lull before the big Nike deal was announced a few years ago. The global packaging partner is named and the scale of ReZorce seen, the company and CEO will continue on its trajectory. Steady hands, safe ship, well positioned.
That is one of its fundamental selling points and why it has the backing of the global packaging supplier.
Ondine certainly seems to be in a sweet spot as it exploits concerns surrounding increased antibiotic resistance. Results of Steriwave look compelling commercially and fundamentally. Word of mouth is spreading in the health arena quickly and York is currently evaluating for NHS rollout. Could be a sleeping giant if things go well.
Start of the commercial rollout schedule is now happening with batch testing on a commercial platform. Preliminary results should be confirmed and the promised substantial increase in uptake ensuing. Lots of time and R&D spent to get to this stage and a lot of press coverage. Let's hope this is the crest of the peak and it's downhill from here as the potential market for ReZorce is huge. The key factor with ReZorce is the fact that it does not require any Capex by the end user (packager) being totally interchangeable with existing machinery.
Sensible, reasoned explanation of status quo and how to begin to address problem.
I'm not a holder but watching. Good solid update but so many times statements of reassurance are a prelude to a price rise that then triggers an 'unexpected' fundraise. I shall watch the rise today and consider again when the imminent spike has passed. Interesting....at a price.